Dublin, Feb. 16, 2017 -- Research and Markets has announced the addition of the "Cryptosporidium Forecast for selected Asian Markets 2017-2027" report to their offering.
Cryptosporidium is a microscopic parasite (Apicomplexan oocyst-forming protozoan) that causes the diarrhoeal disease cryptosporidiosis. Both the parasite and the disease are also known as ""Crypto.""
There are 20 different species of Cryptosporidium; however the main two species that infect humans are C. hominis and C. parvum (also found in bovines). Other species that have been found to infect humans, but are rarer, include C. meleagridis, C. felis, C. canis, C. andersoni, C. suis, C. baylei and C. muris. Within each species, multiple sub-types exist (e.g. Ia, Ib etc).
This report provides the current incident population for Cryptosporidium across Selected Asian Markets (Cambodia, Indonesia, Lao PDR, and Vietnam) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms of Cryptosporidium have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Crypto occurs worldwide, although there are certain factors which can increase its likelihood.
These include:
- Sanitation levels & source of drinking water
- Cohabitation with infected animals
- Age
- Immune status
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography
6. Disease Prognosis & Clinical Course
7. Methodology for quantification of patient numbers
8. Top-line Estimated Incidence for Cryptosporidium
9. Cryptosporidium in Vietnam
10. Abbreviations used in the report
11. Patient-Based Offering
12. Online Pricing Data and Platforms
13. References
14. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/zgm9jp/cryptosporidium
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Gastrointestinal Drugs


Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Instagram Outage Disrupts Thousands of U.S. Users
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



